In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study).
about
"Stormy waters ahead": global emergence of carbapenemases10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of AmericaKinetics of avibactam inhibition against Class A, C, and D β-lactamasesThe β-Lactams Strike Back: Ceftazidime-AvibactamCeftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infectionsReclaiming the efficacy of β-lactam-β-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime.Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.Investigational antimicrobial agents of 2013.Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections.In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates.Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa.Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013.Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa.β-Lactam Antibiotics Renaissance.Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor CombinationsIn Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014).Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients.In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China.Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model.Ceftazidime for respiratory infections.New β-lactam-β-lactamase inhibitor combinations in clinical development.β-Lactamase inhibitors: a review of the patent literature (2010 - 2013).β-lactam/β-lactamase inhibitor combinations: from then to now.Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012.Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections.Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model.Post-hemodialysis dosing of 1 vs. 2 g of ceftazidime in anuric end-stage renal disease patients on low-flux dialysis and its pharmacodynamic implications on clinical use.Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations.In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assaysComparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial.In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates.Avibactam Pharmacokinetic/Pharmacodynamic Targets.Management of bacterial and fungal infections in end stage liver disease and liver transplantation: Current options and future directionsAvibactam confers susceptibility to a large proportion of ceftazidime-resistantPseudomonas aeruginosaisolates recovered from cystic fibrosis patients
P2860
Q21131125-71885414-CDEE-48BE-8A6F-ACC9304BB94CQ24601746-80204F52-0D5A-4358-A97C-18F863D951FAQ24617763-A81A2AD5-EEAB-430F-9BEC-AB8F03B55775Q26796425-6485673D-107D-4324-8CF0-1966C6B97751Q28069563-2DCE6BA2-7D7C-4F81-B5F0-AE1ECD3E8327Q34058217-87B9C8F5-FBC2-4DB4-9B2D-AD92B4EC0623Q34325573-4FDA184F-996C-4C87-9606-84CF599E2A2FQ34375204-7515B441-F337-4A7B-BEE0-80E04F524F4CQ34402134-43B27468-F8DE-4160-B987-119F2BE8FFC7Q34596516-336172E7-DDFB-456B-8137-8361CCD5810BQ35105960-5705F944-226F-412D-8A11-D689338876BCQ35607743-08EB5838-5654-4FEC-B7C5-AE448AEF16ADQ36396244-90D012BB-10A9-4126-9A6E-A9255C4CC5B9Q36683689-A776D098-A751-49CE-82EB-8F9570F4A408Q37055016-FC780EEB-7CB4-4933-8F10-FE6116465ACFQ37120019-CC3945A6-0264-4299-B499-742B7F5BC9F4Q37287753-E7DFBCE6-B0B8-42D7-93F1-4D79814D33FBQ37643595-87AA0B2D-F9F3-467A-A32D-AC11E2A7FDCAQ37643614-EC8BA60E-1170-42DE-9CAE-723583E110D6Q38040144-4C7FFEB5-44EE-440B-9BCE-E81577E28B35Q38076455-E600D50B-4909-47C2-953A-0B262F94363BQ38130715-035ECC74-84FC-4260-A477-B484BF581183Q38264182-16B77ACE-20FB-4DE5-8E7A-BD0A05AE3EAAQ38325959-FD22ABBB-7CFB-4FC0-B16B-4D59C2392273Q38797485-F7799D80-F79A-4AEE-81DD-BB012CB2C4A3Q40375783-329D6C78-D309-4AF9-961D-FA1ED5C71E0AQ40408837-4169C680-95CE-4569-8C14-99398FE15555Q40617746-9A642B1B-E310-4807-A0FD-BDF719C60BE4Q41610058-AD7F197E-99B1-43F4-A405-1EF826015CAEQ42275878-C629F500-55AA-43F6-899A-06ECB24DDBC7Q42598553-4E6584AE-41FC-45A0-8FA3-1E52DC98D35CQ52611981-DE3A4F6B-74CA-4EAF-841E-CD7C5C90587DQ57815117-7A94F385-609A-4173-9093-6BB6A572E410Q57913561-0C4EF9EF-04B0-4FAE-BDAE-4DF53B43E73A
P2860
In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study).
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
In vitro activity of ceftazidi ...... ospitals (CANWARD 2009 study).
@ast
In vitro activity of ceftazidi ...... ospitals (CANWARD 2009 study).
@en
type
label
In vitro activity of ceftazidi ...... ospitals (CANWARD 2009 study).
@ast
In vitro activity of ceftazidi ...... ospitals (CANWARD 2009 study).
@en
prefLabel
In vitro activity of ceftazidi ...... ospitals (CANWARD 2009 study).
@ast
In vitro activity of ceftazidi ...... ospitals (CANWARD 2009 study).
@en
P2093
P2860
P356
P1476
In vitro activity of ceftazidi ...... ospitals (CANWARD 2009 study).
@en
P2093
G G Zhanel
J A Karlowsky
P R S Lagacé-Wiens
P2860
P304
P356
10.1128/AAC.01696-10
P407
P577
2011-03-21T00:00:00Z